Dyax Stock Price, News & Analysis (NASDAQ:DYAX)

Previous Close$38.41
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E Ratio-182.90
Dividend YieldN/A

About Dyax (NASDAQ:DYAX)

Dyax logoDyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.

Receive DYAX News and Ratings via Email

Sign-up to receive the latest news and ratings for DYAX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E Ratio-182.904761904762
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPS($0.21)
Net IncomeN/A
Net Margins-47.32%
Return on Equity-14.86%
Return on Assets-12.09%


Outstanding SharesN/A

Dyax (NASDAQ:DYAX) Frequently Asked Questions

What is Dyax's stock symbol?

Dyax trades on the NASDAQ under the ticker symbol "DYAX."

How were Dyax's earnings last quarter?

Dyax Corp. (NASDAQ:DYAX) posted its earnings results on Wednesday, October, 28th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, meeting the Zacks' consensus estimate of ($0.08). The biopharmaceutical company had revenue of $24.70 million for the quarter, compared to analysts' expectations of $24.96 million. Dyax had a negative net margin of 47.32% and a negative return on equity of 14.86%. The firm's revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.01) earnings per share. View Dyax's Earnings History.

Who are some of Dyax's key competitors?

How do I buy Dyax stock?

Shares of Dyax can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Dyax?

Dyax's mailing address is 55 Network Dr, BURLINGTON, MA 01803-2756, United States. The biopharmaceutical company can be reached via phone at +1-617-2505769.

MarketBeat Community Rating for Dyax (DYAX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  179 (Vote Outperform)
Underperform Votes:  108 (Vote Underperform)
Total Votes:  287
MarketBeat's community ratings are surveys of what our community members think about Dyax and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Dyax (NASDAQ:DYAX) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Dyax (NASDAQ:DYAX) Earnings History and Estimates Chart

Earnings by Quarter for Dyax (NASDAQ:DYAX)

Dyax (NASDAQ DYAX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/28/2015Q315($0.08)($0.08)$24.96 million$24.70 millionViewN/AView Earnings Details
7/29/2015Q215($0.04)($0.06)$23.40 million$264.00 millionViewListenView Earnings Details
4/29/2015Q115($0.05)($0.05)$21.79 million$20.40 millionViewN/AView Earnings Details
2/24/2015Q414($0.04)($0.02)$19.90 million$26.00 millionViewN/AView Earnings Details
10/28/2014Q314($0.06)($0.01)$15.70 million$22.00 millionViewN/AView Earnings Details
7/29/2014Q214($0.05)($0.02)$14.13 million$19.59 millionViewN/AView Earnings Details
4/30/2014Q1 2014($0.05)($0.05)$13.65 million$14.12 millionViewN/AView Earnings Details
2/28/2014Q413($0.04)($0.02)$15.84 million$16.90 millionViewN/AView Earnings Details
10/22/2013Q3 2013($0.05)($0.06)$14.80 million$13.69 millionViewN/AView Earnings Details
7/24/2013Q2 2013($0.06)($0.08)$13.77 million$11.34 millionViewN/AView Earnings Details
4/25/2013Q1 2013($0.05)($0.11)$16.62 million$12.04 millionViewN/AView Earnings Details
2/13/2013Q4 2012($0.05)($0.05)ViewN/AView Earnings Details
10/24/2012Q3 2012($0.08)($0.05)ViewN/AView Earnings Details
7/19/2012Q2 2012($0.09)($0.08)ViewN/AView Earnings Details
4/24/2012Q1 2012($0.09)($0.10)ViewN/AView Earnings Details
2/22/2012Q4 2011($0.10)($0.14)ViewN/AView Earnings Details
10/27/2011Q3 2011($0.13)($0.10)ViewN/AView Earnings Details
4/27/2011Q1 2011($0.11)($0.11)ViewN/AView Earnings Details
2/23/2011Q4 2010($0.11)($0.09)ViewN/AView Earnings Details
10/27/2010Q3 2010($0.13)($0.11)ViewN/AView Earnings Details
7/28/2010Q2 2010($0.14)($0.05)ViewN/AView Earnings Details
4/28/2010Q1 2010($0.15)$0.01ViewN/AView Earnings Details
2/17/2010Q4 2009($0.17)($0.14)ViewN/AView Earnings Details
10/28/2009Q3 2009($0.20)($0.16)ViewN/AView Earnings Details
7/22/2009Q2 2009($0.24)($0.23)ViewN/AView Earnings Details
4/22/2009Q1 2009($0.27)($0.36)ViewN/AView Earnings Details
2/25/2009Q4 2008($0.17)$0.10ViewN/AView Earnings Details
10/22/2008Q3 2008($0.19)($0.29)ViewN/AView Earnings Details
7/23/2008Q2 2008($0.27)($0.41)ViewN/AView Earnings Details
4/24/2008Q1 2008$0.07($0.35)ViewN/AView Earnings Details
2/27/2008Q4 2007($0.29)($0.05)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Dyax (NASDAQ:DYAX) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com


Dividend History for Dyax (NASDAQ:DYAX)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Dyax (NASDAQ DYAX) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Dyax (NASDAQ:DYAX)
Insider Trades by Quarter for Dyax (NASDAQ:DYAX)

Dyax (NASDAQ DYAX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/10/2015Thomas L KempnerDirectorSell6,000$22.47$134,820.0055,041View SEC Filing  
8/28/2015Thomas L KempnerDirectorSell17,947$23.83$427,677.0155,041View SEC Filing  
8/18/2015Thomas L KempnerDirectorSell18,035$23.83$429,774.05View SEC Filing  
8/13/2015Thomas L KempnerDirectorSell4,848$23.81$115,430.88View SEC Filing  
7/20/2015Henry E BlairDirectorSell50,000$27.05$1,352,500.00View SEC Filing  
6/8/2015David J MclachlanDirectorSell75,000$25.63$1,922,250.00View SEC Filing  
3/6/2015Andrew D AsheEVPSell2,400$15.50$37,200.00View SEC Filing  
3/5/2015Burt A AdelmanCMOSell9,375$15.66$146,812.50View SEC Filing  
3/5/2015George V MigauskyCFOSell5,000$15.86$79,300.00View SEC Filing  
3/5/2015Gustav ChristensenCEOSell6,250$15.86$99,125.00View SEC Filing  
2/26/2015Andrew D AsheEVPSell1,500$15.34$23,010.00View SEC Filing  
1/2/2015Burt A AdelmanCMOSell75,000$14.05$1,053,750.00View SEC Filing  
12/5/2014Thomas L KempnerDirectorSell14,764$13.79$203,595.56View SEC Filing  
11/21/2014Thomas L KempnerDirectorSell100,000$13.20$1,320,000.00View SEC Filing  
9/12/2014Thomas L KempnerDirectorSell12,400$11.00$136,400.00View SEC Filing  
8/26/2014Thomas L KempnerDirectorSell37,000$10.39$384,430.00View SEC Filing  
8/19/2014Thomas L KempnerDirectorSell113,755$9.67$1,100,010.85View SEC Filing  
8/7/2014Thomas L KempnerDirectorSell33,190$9.25$307,007.50View SEC Filing  
6/13/2014George V MigauskyCFOSell16,000$8.26$132,160.00View SEC Filing  
3/5/2014Henry BlairDirectorSell150,000$10.46$1,569,000.00353,722View SEC Filing  
3/3/2014Andrew AsheEVPSell30,000$10.00$300,000.0036,277View SEC Filing  
3/3/2014Burt AdelmanCMOSell55,000$9.68$532,400.0037,500View SEC Filing  
2/26/2014Andrew AsheVPSell2,723$10.10$27,502.3012,277View SEC Filing  
12/5/2013Thomas KempnerDirectorSell400,000$8.37$3,348,000.0027,311View SEC Filing  
8/13/2013Andrew AsheVPSell32,500$4.30$139,750.0015,000View SEC Filing  
5/16/2013Marc D KozinDirectorBuy22,971$2.46$56,508.66View SEC Filing  
2/25/2013George V MigauskyCFOSell4,275$3.28$14,022.00View SEC Filing  
2/25/2013Ivana MagovcevicCOOSell4,015$3.24$13,008.60View SEC Filing  
(Data available from 1/1/2013 forward)


Dyax (NASDAQ DYAX) News Headlines

Dyax (DYAX) and vTv Therapeutics (VTVT) Critical ComparisonDyax (DYAX) and vTv Therapeutics (VTVT) Critical Comparison
www.americanbankingnews.com - February 25 at 9:32 AM
Head-To-Head Survey: Dyax (DYAX) and The CompetitionHead-To-Head Survey: Dyax (DYAX) and The Competition
www.americanbankingnews.com - January 3 at 11:30 PM
Dyax (DYAX) vs. The Competition Head to Head AnalysisDyax (DYAX) vs. The Competition Head to Head Analysis
www.americanbankingnews.com - January 1 at 1:22 PM
Contrasting Dyax (DYAX) & Its PeersContrasting Dyax (DYAX) & Its Peers
www.americanbankingnews.com - December 30 at 1:26 AM
Reviewing Dyax (DYAX) and Its PeersReviewing Dyax (DYAX) and Its Peers
www.americanbankingnews.com - December 22 at 9:20 PM
Comparing Dyax (DYAX) & Zosano Pharma (ZSAN)Comparing Dyax (DYAX) & Zosano Pharma (ZSAN)
www.americanbankingnews.com - December 5 at 1:26 PM
Shire Receives European Approval for Label...Shire Receives European Approval for Label...
www.benzinga.com - October 27 at 4:53 AM
Shire Stock Slump Offers Investment Opportunity With Strong Upcoming CatalystsShire Stock Slump Offers Investment Opportunity With Strong Upcoming Catalysts
seekingalpha.com - September 1 at 3:59 AM
AGTC Appoints William Sullivan as Chief Financial Officer, Andrew Ashe Named General CounselAGTC Appoints William Sullivan as Chief Financial Officer, Andrew Ashe Named General Counsel
globenewswire.com - August 2 at 6:56 PM
Ocular Therapeutix™ Appoints George Migausky as Interim Chief Financial OfficerOcular Therapeutix™ Appoints George Migausky as Interim Chief Financial Officer
www.businesswire.com - April 7 at 9:32 AM
Shire Receives FDA Fast Track Designation for Recombinant ADAMTS13 (SHP655) for Treatment of Hereditary ... - PR Newswire (press release)Shire Receives FDA Fast Track Designation for Recombinant ADAMTS13 (SHP655) for Treatment of Hereditary ... - PR Newswire (press release)
www.prnewswire.com - March 22 at 10:01 PM
Shire Reports Full Year 2016 Results With Record Revenue; Positioned for Continued Strong Growth Driven by Best-in ... - PR Newswire (press release)Shire Reports Full Year 2016 Results With Record Revenue; Positioned for Continued Strong Growth Driven by Best-in ... - PR Newswire (press release)
www.prnewswire.com - February 18 at 9:39 AM
Who is the top fee payer to banks in Europe?Who is the top fee payer to banks in Europe?
www.marketwatch.com - January 27 at 6:27 PM
XOMA (XOMA) Sells Two Royalty Streams, Reduces Headcount and ... - StreetInsider.comXOMA (XOMA) Sells Two Royalty Streams, Reduces Headcount and ... - StreetInsider.com
www.streetinsider.com - December 21 at 10:40 PM
XOMA (XOMA) Sells Two Royalty Streams, Reduces Headcount and Names New CEOXOMA (XOMA) Sells Two Royalty Streams, Reduces Headcount and Names New CEO
www.streetinsider.com - December 21 at 5:38 PM

SEC Filings

Dyax (NASDAQ:DYAX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Dyax (NASDAQ:DYAX) Income Statement, Balance Sheet and Cash Flow Statement


Dyax (NASDAQ DYAX) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.